[HTML][HTML] Safety and clinical activity of the programmed death-ligand 1 inhibitor durvalumab in combination with poly (ADP-ribose) polymerase inhibitor olaparib or …
JM Lee, A Cimino-Mathews, CJ Peer… - Journal of Clinical …, 2017 - ncbi.nlm.nih.gov
Journal of Clinical Oncology, 2017•ncbi.nlm.nih.gov
Purpose Data suggest that DNA damage by poly (ADP-ribose) polymerase inhibition and/or
reduced vascular endothelial growth factor signaling by vascular endothelial growth factor
receptor inhibition may complement antitumor activity of immune checkpoint blockade. We
hypothesize the programmed death-ligand 1 (PD-L1) inhibitor, durvalumab, olaparib, or
cediranib combinations are tolerable and active in recurrent women's cancers.
reduced vascular endothelial growth factor signaling by vascular endothelial growth factor
receptor inhibition may complement antitumor activity of immune checkpoint blockade. We
hypothesize the programmed death-ligand 1 (PD-L1) inhibitor, durvalumab, olaparib, or
cediranib combinations are tolerable and active in recurrent women's cancers.
Abstract
Purpose
Data suggest that DNA damage by poly (ADP-ribose) polymerase inhibition and/or reduced vascular endothelial growth factor signaling by vascular endothelial growth factor receptor inhibition may complement antitumor activity of immune checkpoint blockade. We hypothesize the programmed death-ligand 1 (PD-L1) inhibitor, durvalumab, olaparib, or cediranib combinations are tolerable and active in recurrent women’s cancers.
ncbi.nlm.nih.gov